Literature DB >> 6512791

Reducing property of some slow acting antirheumatic drugs.

F Huck, R de Médicis, A Lussier, G Dupuis, P Federlin.   

Abstract

Many slow acting antirheumatic drugs and several other drugs without antirheumatic activity possess a potential thiol function, i.e., a free SH group or one that is generated by hydrolysis. Since drugs with effective SH activity may react with intracellular disulfides, we evaluated their reducing properties by measuring their redox potential and their ability to react with glutathione, the most prevalent intracellular thiol, and dithiobis (nitrobenzoic acid), a specific reactant for thiols. Drugs containing aromatic thiols are poor reducers and are generally devoid of antirheumatic activity. Antirheumatic drugs, such as D-penicillamine, levamisole, gold salts, thiopronine and captopril, are potential aliphatic thiols with strong reducing properties. These different antirheumatic drugs may therefore operate by a common mechanism through an altered cellular redox equilibrium and sulfide-disulfide exchanges.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6512791

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

1.  Long-term low dose ticlopidine treatment in rheumatoid arthritis: effects on serum sulphydryl levels, technetium index, erythrocyte sedimentation rate, and clinical disease activity.

Authors:  M G Grimaldi
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  How adverse drug reactions can play a role in innovative drug research.

Authors:  F Rikken; R Vos
Journal:  Pharm World Sci       Date:  1995-11-24

3.  The effect of angiotensin-converting enzyme inhibitors on human neutrophil chemotaxis in vitro.

Authors:  M Clapperton; J McMurray; A C Fisher; H J Dargie
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

4.  Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes.

Authors:  Karl E Carlström; Ewoud Ewing; Mathias Granqvist; Alexandra Gyllenberg; Shahin Aeinehband; Sara Lind Enoksson; Antonio Checa; Tejaswi V S Badam; Jesse Huang; David Gomez-Cabrero; Mika Gustafsson; Faiez Al Nimer; Craig E Wheelock; Ingrid Kockum; Tomas Olsson; Maja Jagodic; Fredrik Piehl
Journal:  Nat Commun       Date:  2019-07-12       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.